Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients

作者
Kyota Shinfuku,Hiromichi Hara,Keitaro Okuda,Hanae Miyagawa,Naoki Takasaka,Takeo Ishikawa,Jun Araya
出处
期刊:BMC Pulmonary Medicine [BioMed Central]
卷期号:25 (1): 67-67 被引量:3
标识
DOI:10.1186/s12890-025-03504-4
摘要

BACKGROUND: Mycobacterium avium complex pulmonary disease (MAC-PD) is considered to be increasing worldwide. In Japan, the number of elderly MAC-PD patients requiring treatment is also expected to increase due to the aging society. However, reduced organ function in elderly patients makes it often difficult to continue or complete multidrug treatment due to adverse drug reactions (ADRs). Therefore, this study aimed to identify clinical factors associated with treatment tolerability, efficacy, and ADRs in elderly MAC-PD patients. METHODS: We retrospectively reviewed the medical records of 102 patients with MAC-PD aged ≥ 75 years between January 2014 and March 2023. Forty-six patients were treated with multidrug regimens (treatment group), and 56 were observed without treatment (observation group). The treatment group was divided into the treatment continuation group (n = 28) who were treated without interruption for ≥ 12 months, and the treatment interruption group (n = 18). A comparative study was conducted in each group to examine tolerability, efficacy, and ADRs. RESULTS: A two-drug regimen of ethambutol (EB) and macrolides without rifampicin (RFP) was associated with treatment continuation (p = 0.026). The treatment continuation group was superior to the observation group regarding symptoms change, sputum conversion rate, and chest computed tomography scores. The most common ADRs were gastrointestinal disorders, which may be related to RFP. Treatment efficacy of the two-drug regimen was non-inferior, and no cases of macrolide resistance were observed. CONCLUSIONS: The two-drug regimen of EB and macrolide without RFP may be a tolerable and effective treatment for elderly MAC-PD patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zc完成签到,获得积分10
刚刚
Tin完成签到,获得积分10
1秒前
hh完成签到 ,获得积分10
1秒前
刻苦绿蕊完成签到,获得积分10
3秒前
李伟完成签到,获得积分10
3秒前
Sure完成签到 ,获得积分10
3秒前
曾珍完成签到 ,获得积分10
6秒前
青云万里完成签到,获得积分10
6秒前
142857完成签到,获得积分10
8秒前
Una2030完成签到 ,获得积分10
12秒前
轻松香菇完成签到 ,获得积分10
13秒前
Jeffrey完成签到,获得积分10
14秒前
房杨完成签到,获得积分10
14秒前
七七完成签到 ,获得积分10
15秒前
怡然铭完成签到 ,获得积分10
16秒前
黄芪完成签到,获得积分10
20秒前
高山流水完成签到,获得积分10
21秒前
lingling00完成签到 ,获得积分10
22秒前
山野的雾完成签到 ,获得积分10
23秒前
沉静梦蕊完成签到,获得积分10
27秒前
枯叶灬风发布了新的文献求助10
29秒前
微笑完成签到,获得积分10
29秒前
myyyyy完成签到,获得积分10
30秒前
不摸鱼上啥班完成签到,获得积分10
30秒前
hdbys完成签到,获得积分10
30秒前
romeo完成签到,获得积分10
31秒前
36秒前
科研孙一完成签到,获得积分10
37秒前
franklylyly完成签到,获得积分10
37秒前
爱吃菠萝的大葱完成签到,获得积分10
39秒前
Tonald Yang发布了新的文献求助10
39秒前
qing完成签到 ,获得积分10
39秒前
一杯半茶完成签到 ,获得积分10
39秒前
qiuy发布了新的文献求助10
44秒前
陈少华完成签到 ,获得积分10
45秒前
烟火会翻滚完成签到,获得积分10
46秒前
蜡笔小新完成签到 ,获得积分10
48秒前
mimilv完成签到,获得积分10
49秒前
ChengYonghui完成签到,获得积分10
50秒前
知画春秋完成签到 ,获得积分10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180097
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808841
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479013